Marico Limited has acquired an additional 24.09% equity stake in Satiya Nutraceuticals Private Limited for a cash consideration of ₹1,012.03 crore. This transaction increases Marico’s aggregate holding in the subsidiary from 60% to 84.09% on a fully diluted basis.

The acquisition was completed on October 5, 2026, pursuant to definitive agreements entered into with the founders and certain other shareholders of Satiya Nutraceuticals. The move aligns with Marico’s strategic intent to expand its total addressable market in value-added foods and nutrition segments, as well as rapidly growing personal care and wellness categories.

Transaction details and timeline

The current tranche represents part of a broader agreement under which Marico holds rights to acquire the remaining 40% stake in Satiya Nutraceuticals. Following this acquisition, the company retains the option to purchase the residual 15.91% stake (specifically the remaining 14.09% held by founders and other shareholders) in July 2027.

The consideration for the future tranche will be determined at that time, comprising a base amount of up to ₹592 crore plus additional consideration subject to specific milestones and terms outlined in the definitive agreements. The entire transaction is structured as a cash deal, with no share swap involved.

Target entity profile

Satiya Nutraceuticals Private Limited, incorporated in February 2020 and headquartered in Mumbai, owns the brand The Plant Fix – Plix. The brand operates in the health, wellness, and personal care industry, focusing on plant-based nutrition products. The company also has a wholly owned subsidiary, Juizo Advisory Private Limited.

The acquisition is classified as a related party transaction because it involves the purchase of stakes held by the founders of Satiya Nutraceuticals and their relatives or related entities. However, Marico stated that these transactions are conducted on an arm’s length basis. The promoter group of Marico does not hold any interest in the target entity.

Financial performance of Satiya

Satiya Nutraceuticals has demonstrated significant revenue growth over the past three fiscal years. The consolidated turnover figures highlight the rapid scaling of the Plix brand within the consumer health market.

What the numbers show

The data reveals a sharp acceleration in Satiya’s top-line performance, with turnover more than doubling from FY25 to FY26. This growth trajectory likely supports the valuation implied by the ₹1,012.03 crore payment for a 24.09% stake. With Marico now holding an 84.09% majority, the financial results of Satiya will be fully consolidated into Marico’s books, directly impacting its revenue mix in the nutrition and personal care segments.

Marico Limited reported robust operating performance for the quarter ended September 30, 2026, with domestic volume growth touching double digits. The company stated that with strong growth, it is likely to surpass guidance across key financial parameters.

The India business maintained strong momentum, driven by Parachute Coconut Oil which accelerated to early teens volume growth. Value Added Hair Oils delivered its sixth consecutive quarter of stellar growth, reaching twenties percent growth. Saffola Oils recorded mid-single digit price-led growth, though volumes declined as the company rationalized supply to maintain profitability thresholds.

International operations contributed significantly to the top line, with constant currency growth in the teens led by Vietnam, the Middle East, and South Africa. Bangladesh saw marginal sequential improvement despite lapping a high base amid elevated inflation. The overseas portfolio continues to support diversification efforts alongside digital-first brands and premium personal care segments.

Input Costs and Margin Dynamics

The company highlighted a favorable environment for gross margins due to input cost trends. Copra prices remained rangebound at approximately 35% below peak levels, providing a significant tailwind. Conversely, the cost of crude-linked derivatives elevated further during the period. Management expects strong acceleration in gross margin on a year-on-year basis, aided by this copra price advantage and a favourable portfolio mix.

What the Numbers Show

A divergence exists between pricing power and volume dynamics across categories. While Saffola Oils prioritized profitability through price-led growth at the expense of volume, Parachute and Value Added Hair Oils achieved significant volume expansion. This suggests a bifurcated strategy where core high-equity brands drive volume, while other segments manage margin thresholds. Additionally, the expectation of mid-twenties operating profit growth against double-digit revenue growth indicates substantial operating leverage, likely driven by the copra price tailwinds mentioned in the update.

The company remains optimistic on consumption trends despite volatile operating conditions. With a strong first half, Marico is likely to surpass near-term guidance across key financial parameters. Investments in brand building and growth initiatives increased ASP (Advertising and Sales Promotion) costs, but these were offset by gross margin expansion. The medium-term aspiration remains sustainable and profitable volume-led growth.